At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
CE-224,535 +1 moredrug
Likely dose
CE-224,535 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE
In Brief
A Phase 2 clinical trial evaluating CE-224,535 and Placebo for Arthritis, Rheumatoid. Completed, enrolled 100 participants across 27 sites in 7 countries.
Detailed Summary
CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesChile, Czechia, Mexico, Poland, South Korea, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartApr 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedMar 4, 2008
Enrollment StartApr 7, 2008
Primary CompletionFeb 4, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.3 years ago
Interventions
CE-224,535drug
500 mg po BID
Placebodrug
no active ingredient